Cotellic

Cotellic (Cobimetinib Fumarate) is an anticancer drug used to treat inoperable or metastatic melanoma with a BRAF V600 mutation in adult patients in combination with vemurafenib.

The pathway of mitogen-activated protein kinase (MAPK) / extracellular signal-regulated ERK kinase (extracellular signal-regulated kinase) is the main signal transduction pathway that regulates cell proliferation, cell cycle, cell viability, angiogenesis, and cell migration.

Cobimetinib is an oral, highly selective allosteric kinase inhibitor MEK1 / 2 (MAPK / ERK kinase). In biochemical and cytological studies, cobimetinib has demonstrated a high inhibitory ability as well as activity against a wide range of tumors, including those carrying the BRAF and KRAS mutations.

In biochemical and structural studies, the interaction of cobimetinib with MEK was shown, with little sensitivity to the dynamic conformational changes observed during the transition of MEK to the phosphorylated form. As a result, cobimetinib retains binding ability and inhibitory activity during MEK phosphorylation. Cobimetinib showed the highest activity against tumor cell lines and tumors with high levels of MEK phosphorylation, which is often observed in tumors with BRAF mutations.

Always follow your doctor`s instructions when using Cotellic (Cobimetinib Fumarate) to get the safest and most effective results from treatment.

Treatment with Cotellic (Cobimetinib Fumarate) in combination with vomurafenib should be initiated and supervised by a qualified physician experienced in the appointment of antitumor drugs.

Therecommended dose of Cotellic (Cobimetinib Fumarate) is 60 mg (3 tablets of 20 mg) once a day.

The drug Cotellic (Cobimetinib Fumarate) is taken during a 28-day course. Each dose consists of three 20 mg tablets (60 mg) that should be taken once a day for 21 days continuously (from day 1 to day 21), and then take a 7-day break (from 22nd day till the 28th day). Each subsequent course of treatment with the drug Cotellic (Cobimetinib Fumarate) should be started within 7 days of a break in treatment.

The use of Cotellic (Cobimetinib Fumarate) may cause side effects in some patients including:

• anemia
• serus retinopathy
• reduced visual acuity
• visual impairment
• diarrhea
• nausea
• vomiting
• stomatitis
• dehydration
• hypophosphatemia
• hyponatremia
• hyperglycemia
• photosensitivity

Contact your doctor immediately if you experience any serious or worrying symptoms.

Before the start of this treatment, patients should confirm the positive status of BRAF V600 melanoma mutations with a validated test.